人表皮生长因子受体2阳性乳腺癌的靶向治疗研究进展  

Research progress of targeted therapy in human epidermal growth factor receptor-2 positive breast cancer

作　　者：韩萌萌 冯雪园 马宁[1] Han Mengmeng;Feng Xueyuan;Ma Ning(The Second Department of Breast Surgery,Baoding NO.1 Central Hospital,Baoding 071000,China)

机构地区：[1]保定市第一中心医院乳腺外二科,071000

出　　处：《中华普通外科学文献（电子版）》2021年第6期453-458,共6页Chinese Archives of General Surgery(Electronic Edition)

摘　　要：乳腺癌的靶向治疗因其特异性强,毒性不良反应小,已成为继手术、放疗、化疗等传统治疗之外的一种重要治疗手段。人表皮生长因子受体2(HER-2)阳性乳腺癌侵袭性强、预后差,曲妥珠单抗的问世改善了HER-2阳性乳腺癌的预后。此后,一系列抗HER-2靶向治疗药物相继用于临床研究及治疗,包括帕妥珠单抗、拉帕替尼、来那替尼、吡咯替尼以及曲妥珠单抗-美坦新偶联物等。本文就不同作用机制的抗HER-2治疗药物对HER-2阳性乳腺癌的靶向治疗现状作一综述。Traditional treatments for breast cancer include surgery,radiotherapy and chemotherapy.Targeted therapy has become an important treatment method for breast cancer because of its strong specificity and low toxicity.Human epidermal growth factor receptor-2(HER-2)positive breast cancer has strong invasiveness and poor prognosis.The advent of trastuzumab improves the prognosis of HER-2-positive breast cancer.Since then,a series of anti-HER-2 targeted therapies have been used for clinical research and treatment,including pertuzumab,lapatinib,lenatinib,pyrotinib and ado-trastuzumab emtansine.This article reviews the current status of anti-HER-2 drugs with different mechanisms of action in the targeted therapy of HER-2-positive breast cancer.

关 键 词：乳腺肿瘤 靶向治疗 受体 表皮生长因子 HER-2 

分 类 号：R737.9[医药卫生—肿瘤]